Effect of Ad35K⁺⁺ on rituximab therapy in Farage xenograft model. (A) Distribution of human CD20⁺ Farage cells. Note the follicular tumor growth, particularly in the spleen. (B) Treatment scheme. Treatment was started at day 21 after intravenous injection of Farage cells. (C) Flow cytometry for huCD20 cells; n = 7. The differences between rituximab and Ad35K⁺⁺/rituximab are significant for all 3 tissues (P < .03). (D) Kaplan-Meier survival study after 1 round of treatment; n = 7.